Prior to founding Juniper Point, Amy spent 13 years as head of investor relations and corporate communications at San Diego biotech companies Anadys Pharmaceuticals (acquired by Roche in 2011) and Regulus Therapeutics (RGLS), acting as the primary Wall-Street facing leader and solidifying deep relationships with market-moving analysts, bankers, and buy-siders. She has extensive expertise in building and financing companies across multiple therapeutic modalities including small molecules, biologics, and RNA therapeutics, and has been involved in eight IPO processes, numerous follow-on transactions, and pharma partnerships.

Amy was born and raised in California and has called San Diego home since 2003. She is passionate about the San Diego biotechnology ecosystem and where the community fits into the broader, global landscape. She has been a past president of the National Investor Relations Institute (NIRI) and is a frequent speaker on industry panels.

When she’s not working, you can find Amy on the basketball court, riding her bike, or playing with her son and dogs Taco and Chili.